Report of Foreign Issuer (6-k)
August 08 2019 - 4:33PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
W
ashington,
D.C.
20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of August 2019
Commission
File Number: 001-37643
KITOV
PHARMA
LTD.
(Translation
of registrant’s name into English)
One
Azrieli Center, Round Tower,
132
Menachem Begin Road, Tel Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On
August 8, 2019, Kitov Pharma
Ltd. (the “Company” or the “Registrant”) issued a Press
Release: “
Kitov Pharma Reports First Half 2019 Financial Results and Provides Business Update
”. A copy of
this press release, together with the Company’s Condensed Consolidated Unaudited Interim Financial Statements as of
June 30, 2019, and for the six months then ended, are furnished herewith as Exhibits 99.1 and 99.2, respectively.
The
information contained within this report on Form 6-K and all Exhibits attached hereto should be read in conjunction with
(1) our Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2019, and for the six months then
ended; and, (2) our audited consolidated financial statements for the year ended December 31, 2018, which appears in
the Company’s Annual Report on
Form
20-F
filed with the Securities and Exchange Commission on March 26, 2019 (as amended by the
Form 20-F/A
amendment filed
on April 3, 2019), as well as the other information contained in such Annual Report on Form 20-F and in our
Registration Statements and Prospectuses filed with the SEC.
The text which is found under the heading
entitled “Financial Results for Six-Month Period Ended June 30, 2019” in Exhibit 99.1 attached hereto; and, the entire
Exhibit 99.2 attached hereto, are all hereby
incorporated by reference into each of
the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016
(Registration file numbers
333-207117
,
333-211477
and
333-215037
),
the Registrant’s Registration Statement on
Form
S-8
filed with the Securities and Exchange Commission on May 20, 2016 (Registration
file number
333-211478
), the Registrant’s Registration Statement on
Form S-8
filed with the Securities and Exchange Commission on June 6, 2017 (Registration
file number
333-218538
), the Registrant’s Registration Statement on
Form F-3
, as amended, originally filed with the Securities and Exchange Commission
on July 16, 2018 (Registration file number
333-226195
), and the Registrant’s Registration Statement on
Form
S-8
filed with the Securities and Exchange Commission on March 28, 2019 (Registration
file number
333-230584
).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
KITOV PHARMA LTD.
|
|
|
|
August 8, 2019
|
By:
|
/s/
Isaac Israel
|
|
|
Isaac Israel
|
|
|
CEO & Director
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Apr 2023 to Apr 2024